This study evaluates whether the time of day when immunotherapy is given affects clinical outcomes. It includes patients eligible for PD-1 (programmed cell dea…

Lung CancerNon-small Cell Lung CancerMetastatic Lung Cancer+4 more

~Estimated

~$10 – $6,250

UNC Lineberger Comprehensive Cancer CenterNCT07630168

Phase 2

A Phase 2 Trial of PD-L1 t-haNK, NAI IL-15 Superagonist (Anktiva), and Cetuximab for Immunotherapy-treated Patients With Recurrent, Metastatic HNSCC (QUILT-505)

The purpose of this research study is to test the safety and efficacy of the combination of PD-L1 t-haNK (modified immune cells), NAI (a manufactured protein t…

Head and Neck CancerHead and Neck Squamous Cell CarcinomaMetastatic Head and Neck Cancer+3 more

~Estimated

~$10 – $7,500

Dana-Farber Cancer InstituteNCT06239220

Phase 1

Feasibility Trial of Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

This is a feasibility trial studying anti-PD-1 therapy (Pembrolizumab) among patients with R/M HNSCC, delivered with ultrasound-induced microbubble cavitation,…

Head and Neck CancerHead and Neck Small Cell CarcinomaMetastatic Head and Neck Cancer+1 more

~Estimated

~$10 – $6,250

Thomas Jefferson UniversityNCT07501650